#LCSM Chat Topic 22-Feb-2018: Lung cancer research–Why we need it and how we can get more
“Cancer research” is a broad term that encompasses everything from basic bench science, to translational research on patient-derived tumor specimens, to clinical trials, to studies on patient centered outcomes. While it is obvious to all of us in the lung cancer community that research is critical to improving patient outcomes, lung cancer remains underfunded compared to other common cancers. Several different mechanisms exist to fund cancer research, including private philanthropy, Big Pharma, not-for-profit cancer research and advocacy groups, and government organizations including the DOD and NIH/NCI among others. Given funding imbalances, it… Read More
#LCSM Chat Topic 2/8/18: Right to Try Laws and CIMAVax
“Right to Try” laws for people with a terminal illness have been a longstanding issue and are currently on the books in 38 states. The lack of a federal law supporting this concept was touched upon in President Trump’s State of the Union address last week. On its face, offering liberal options that permit these patients to try any still investigational agent that has completed phase I testing seems like a benefit to patients who may be desperate for options. A couple of arguments in favor of it are available here:… Read More
#LCSM Chat Topic 12/14: #LCSM Community 2017 Highlights, Visions for 2018
By just about any measure, 2017 has been a banner year in lung cancer management for the lung cancer community. Here is just a partial list of some of the key highlights: Growing use of stereotactic ablative body radiation (SABR) for patients with unresectable early stage disease Increasing momentum for local therapies, including surgery and/or radiation, for isolated residual disease after systemic therapy even for more advanced NSCLC A likely new standard of care for unresectable stage III NSCLC, with addition of immunotherapy, after more than a decade without any treatments proven… Read More
#LCSM 
You must be logged in to post a comment.